Today’s Top Stocks Under $1

Over the past few years, an unprecedented bull run has led to many stocks becoming overvalued, however, there are still many stocks under a dollar which value investors can look to for discounts and growth opportunities. 

In this column, we try to highlight some of the day’s best opportunities under $1 per share.

Isoray, Inc. (NYSE:ISR) closed Monday at $0.6312 on above-average trading volume.  The company will be releasing Q4 and fiscal year-end results for 2021 today.  ISR’s stock price peaked at $2.47 in late January, now trading at 63 cents, it will be interesting to see how investors react to today’s numbers.

Allied Energy Corp. (OTCMKTS:AGYP) announced last week that it achieve oil production at their Green Lease in North Texas.  The company is also close to production on their Texas-based Annie Gilmer lease.  Trading volume has been up since the announcement.  Short interest has fluctuated and the stock price has been extremely volatile bouncing between the low 30s and low 40s.  Currently, at the low end of the channel, the stock could bounce from here today.

Pure Gold Mining Inc. (OTCMKTS:LRTNF) has had a nice run of positive news over the past month.  The company recently announced reaching production milestones and several upgrades at their “high-grade PureGold Mine” in Red Lake, Ontario.  LRTNF insider, Christopher Haubrich, recently shelled out CA$102k to buy stock, at CA$1.02 per share of Pure Gold’s Toronto listing PGM which is a positive signal for investors.

Progenity Inc. (NASDAQ:PROG) a biotechnology company, recently announced securing a patent (U.S. Patent No. 11,112,403) for assessment of preeclampsia using assays for free and dissociated placental growth factor.  The patent is directed to methods, compositions, and kits for detecting and measuring free and dissociated placental growth factor (PlGF) levels in biological samples. PlGF is well established as an important biomarker for the assessment of preeclampsia, and recent studies have revealed the importance of distinguishing between the free and bound forms when assessing the complex physiological pathways involved in preeclampsia.